RANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rani Therapeutics Holdings Inc (RANI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no significant positive catalysts or trading signals to support an immediate investment. The stock's price trend and lack of financial and news data suggest waiting for more clarity on the company's performance or a more favorable entry point.
The technical indicators for RANI are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 39.553, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.806, with key support at 0.742 and resistance at 0.87.
The company has initiated a Phase I clinical study in Australia for RT-114, a GLP-1/GLP-2 dual agonist for obesity treatment, which could yield results in 2H26.
No significant news or trading trends from hedge funds or insiders. Analysts have lowered the price target from $9 to $5, reflecting a more cautious outlook. The stock's implied volatility is very high (633.41), indicating significant risk.
No financial data available for analysis.
Canaccord has maintained a Buy rating but lowered the price target from $9 to $5, reflecting a cautious outlook after the company's 4Q25 and FY2025 results.
